Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABILIFY MAINTENA KIT vs ANGIOTENSIN ll ACETATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing dopamine and serotonin activity.
Angiotensin II acetate is a synthetic peptide that acts as a potent vasoconstrictor by binding to the angiotensin II type 1 (AT1) receptor on vascular smooth muscle cells, leading to increased intracellular calcium and smooth muscle contraction. It also stimulates aldosterone secretion from the adrenal cortex, promoting sodium and water retention.
Treatment of schizophrenia,Maintenance monotherapy for bipolar I disorder,Adjunctive treatment of major depressive disorder (off-label),Irritability associated with autistic disorder (off-label),Tourette's disorder (off-label)
Treatment of hypotension in adults with septic or other distributive shock (FDA approved)
400 mg IM once monthly after establishing tolerability with oral aripiprazole.
Intravenous infusion: 1-40 ng/kg/min titrated to achieve target blood pressure. Initial rate: 10 ng/kg/min.
Aripiprazole: 75-146 hours; dehydro-aripiprazole: 94-146 hours. Long half-life allows monthly intramuscular dosing.
Terminal elimination half-life is approximately 30-60 minutes; clinical effect is short-lived requiring continuous intravenous infusion.
Primarily hepatic via CYP2D6 and CYP3A4; active metabolite dehydro-aripiprazole.
Primarily metabolized by aminopeptidases and other peptidases in plasma and tissues, with minimal hepatic involvement.
Renal (approximately 25% unchanged and 55% as metabolites); fecal (approximately 20% as metabolites).
Primarily renal (90-100%) as unchanged drug; minimal biliary/fecal elimination (<10%).
Aripiprazole is >99% bound to serum albumin and alpha-1-acid glycoprotein.
Approximately 30% bound to plasma proteins, primarily albumin.
Aripiprazole: 4.9 L/kg (range 3.7-7.2 L/kg), indicating extensive tissue distribution.
Approximately 0.3-0.5 L/kg; indicates distribution mainly in extracellular fluid.
IM (Abilify Maintena): 100% relative to oral aripiprazole after 5 monthly doses; oral: 87%.
Intravenous: 100%; subcutaneous/intramuscular: not well absorbed due to rapid local metabolism; oral: negligible (<1%) due to extensive first-pass metabolism.
No adjustment for mild/moderate impairment; caution in severe impairment (Cr Cl <30 m L/min).
No specific dose adjustment required for renal impairment. Use caution in patients with renal artery stenosis.
No adjustment for mild impairment; moderate to severe (Child-Pugh class B or C): reduce dose to 300 mg/month.
No specific dose adjustment required for hepatic impairment.
Not approved for pediatric use.
Intravenous infusion: 0.5-20 ng/kg/min titrated to effect. Safety and efficacy not established in neonates.
Use cautiously due to increased sensitivity; consider lower doses and monitor for adverse effects.
Start at lower end of dosing range (1-5 ng/kg/min) due to potential for decreased renal function and increased sensitivity.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
No boxed warnings.
Increased mortality in elderly dementia patients; suicidal thoughts and behaviors; neuroleptic malignant syndrome; tardive dyskinesia; metabolic changes (hyperglycemia, dyslipidemia, weight gain); orthostatic hypotension; leukopenia/neutropenia; seizure risk; dysphagia; body temperature dysregulation; pathological gambling and other impulse control disorders.
Thrombotic and thromboembolic events: Increased risk of venous and arterial thromboembolic events, including deep vein thrombosis, pulmonary embolism, and myocardial infarction.,Ischemic events: May cause cardiac ischemia and reduce cardiac output; use with caution in patients with coronary artery disease.,Vascular thrombosis: High risk of vascular thrombosis in patients with a history of thrombosis or hypercoagulable states.,Use in hypovolemia: Correct hypovolemia before administration to avoid exacerbation of vasoconstriction.,Pregnancy: May cause fetal harm; avoid use in pregnant women unless potential benefit outweighs risk.
Hypersensitivity to aripiprazole or any excipients in the formulation.
Hypersensitivity to angiotensin II acetate or any component of the formulation,No absolute contraindications listed by the manufacturer; however, use is avoided in patients with uncorrected hypovolemia and those with a history of thromboembolic events.
No specific food interactions. Grapefruit/grapefruit juice may increase aripiprazole levels (CYP3A4 inhibition). Avoid excessive alcohol consumption.
No food interactions specific to angiotensin II acetate. Maintain a balanced diet as tolerated. Avoid excessive salt intake unless directed otherwise, as it may counteract the medication's effect on blood pressure.
First trimester: Limited data, but aripiprazole is not a major human teratogen based on available studies. Second and third trimesters: Neonates exposed to antipsychotics, including aripiprazole, during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms post-delivery.
First trimester: Potential for teratogenicity (increased risk of cardiovascular and CNS malformations). Second and third trimesters: Fetal hypotension, anuria, oligohydramnios, skull hypoplasia, pulmonary hypoplasia, and death. Use contraindicated in pregnancy.
Aripiprazole is excreted in human breast milk; the estimated infant dose is 0.7–1.4% of maternal weight-adjusted dose. M/P ratio: approximately 0.3–0.5. Limited data suggest no adverse effects in breastfed infants, but long-term safety is unknown.
No data on M/P ratio. Likely excreted in breast milk. Avoid breastfeeding due to unknown risks to neonate.
No specific dose adjustment recommended based on pharmacokinetic changes; however, therapeutic drug monitoring may be considered due to altered metabolism in pregnancy. The long-acting injectable formulation (Abilify Maintena) requires careful timing of doses postpartum to avoid relapse.
No dose adjustment recommended if used; however, if inadvertently exposed, discontinue drug. Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced clearance) may lower drug levels, but no established dose adjustment.
Administer every 4 weeks by intramuscular injection only. Do not substitute for oral aripiprazole on a mg-per-mg basis due to different pharmacokinetics. Requires initiation and continuation with oral aripiprazole for 14 days to establish tolerability. Monitor for neuroleptic malignant syndrome, tardive dyskinesia, and metabolic changes. Dose adjustments needed in patients with known CYP2D6 poor metabolizer status or concurrent use of strong CYP2D6 or CYP3A4 inhibitors.
ANGIOTENSIN II ACETATE is a vasoconstrictor used for refractory hypotension in distributive shock. Administer via central line to avoid extravasation, which can cause severe tissue ischemia. Monitor blood pressure every 5 minutes during titration. Discontinue other vasopressors if possible to avoid additive arrhythmogenic effects. Use with caution in patients with coronary artery disease or previous myocardial infarction due to increased oxygen demand. Taper gradually to avoid rebound hypotension.
This medication is given as an injection every 4 weeks by a healthcare professional.,Do not stop taking your oral aripiprazole until your doctor tells you to.,Seek emergency care if you experience fever, muscle stiffness, confusion, or irregular heartbeat.,Avoid alcohol and driving until you know how this medicine affects you.,Report any uncontrolled movements of the face, tongue, or other body parts to your doctor.,Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
This medication is given intravenously in the hospital to raise very low blood pressure. You will be closely monitored during treatment.,Inform your healthcare provider immediately if you experience chest pain, difficulty breathing, or irregular heartbeat.,Avoid sudden position changes to prevent dizziness, as blood pressure may fluctuate.,Report any pain, swelling, or color changes at the injection site, which could indicate medication leakage.,You may need regular blood tests to monitor kidney function and electrolyte levels.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABILIFY MAINTENA KIT vs ANGIOTENSIN ll ACETATE, answered by our medical review team.
ABILIFY MAINTENA KIT is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing dopamine and serotonin activity.. ANGIOTENSIN ll ACETATE is a Vasopressor that works by Angiotensin II acetate is a synthetic peptide that acts as a potent vasoconstrictor by binding to the angiotensin II type 1 (AT1) receptor on vascular smooth muscle cells, leading to increased intracellular calcium and smooth muscle contraction. It also stimulates aldosterone secretion from the adrenal cortex, promoting sodium and water retention.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABILIFY MAINTENA KIT and ANGIOTENSIN ll ACETATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABILIFY MAINTENA KIT is: 400 mg IM once monthly after establishing tolerability with oral aripiprazole.. The standard adult dose of ANGIOTENSIN ll ACETATE is: Intravenous infusion: 1-40 ng/kg/min titrated to achieve target blood pressure. Initial rate: 10 ng/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABILIFY MAINTENA KIT and ANGIOTENSIN ll ACETATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABILIFY MAINTENA KIT is classified as Category C. First trimester: Limited data, but aripiprazole is not a major human teratogen based on available studies. Second and third trimesters: Neonates exposed to antipsychotics, includin. ANGIOTENSIN ll ACETATE is classified as Category C. First trimester: Potential for teratogenicity (increased risk of cardiovascular and CNS malformations). Second and third trimesters: Fetal hypotension, anuria, oligohydramnios, sku. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.